{"id":"NCT04642469","sponsor":"AstraZeneca","briefTitle":"Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.","officialTitle":"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-30","primaryCompletion":"2023-05-31","completion":"2024-01-15","firstPosted":"2020-11-24","resultsPosted":"2024-06-25","lastUpdate":"2024-06-25"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non- Small Cell Lung"],"interventions":[{"type":"DRUG","name":"Durvalumab","otherNames":["Medi4736"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Durvalumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.","primaryOutcome":{"measure":"Disease-free Survival (DFS)","timeFrame":"Every 8 weeks (q8w) ± 1 week until Week 48, then every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or follow-up, up to 16.6 months","effectByArm":[{"arm":"Durvalumab","deltaMin":3.9,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":115,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Czechia","France","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Netherlands","Peru","Poland","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","Vietnam"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D910MC00001&amp;attachmentIdentifier=87ff8c14-5d81-4b1e-917e-b062d63d134e&amp;fileName=d910mc00001-csp-v2_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D910MC00001&amp;attachmentIdentifier=1109be20-4d3e-4900-8faa-73cd619fda9e&amp;fileName=d910mc00001-sap-ed-2_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D910MC00001&amp;attachmentIdentifier=2ca4ff82-8586-4b4b-b79e-ca8e45144b18&amp;fileName=d910mc00001-abbreviated-study-synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":14},"commonTop":["Hypothyroidism","Asthenia","Pruritus","Rash","Diarrhoea"]}}